Table 3.
Choice of therapy in followed up patients
| Type of disease modifying therapy | All (n:157) | MS and AID (n:24) | MS without AID (n:133) | MS and ABF (n: 35) | MS without AID and without ABF (n: 98) |
|---|---|---|---|---|---|
| None, n (%) | 30 (19.1) | 3 (12.5) | 27 (20.3) | 9 (25.7) | 18 (18.4) |
| Low efficacy, n (%) | 115 (73.2) | 18 (75) | 97 (72.9) | 24 (68.6) | 73 (74.5) |
| Intermediate efficacy, n (%) | 5 (3.2) | 2 (8.3) | 3 (2.3) | 1 (2.9) | 2 (2) |
| High efficacy, n (%) | 7 (4.5) | 1 (4.2) | 6 (4.5) | 1 (2.9) | 5 (5.1) |
AID, autoimmune disease; ABF, isolated antibody finding; low potency therapy: azathioprine, methotrexate, teriflunomide, dimethyl fumarate, interferon beta and glatiramer acetate; intermediate potency: fingolimod; high potency disease-modifying therapies: alemtuzumab, rituximab, natalizumab